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1 Introduction 
The academic consideration of procurement is
sometimes very simplistic. In many cases, procure-
ment is neglected as an important value creation
lever for the company or the definition and con-
sideration is just not sufficient. This is illustrated
by the fact that main definitions in academia limit
procurement to a process focused department for
sourcing goods in the right quality to the right place
at the right time at minimum costs. Even in Porter’s
value chain analysis concept (Porter, 1985), procure-
ment is seen as a supporting activity which under-
lines the lack of importance for procurement in this
framework. Procurement is by far more important
than these definitions indicate and has for decades
not been the main department for aspiring young
professionals. This picture has changed recently
and procurement is now more and more attract-
ing young professionals. As procurement depart-
ments develop from an internal service provider to
value champions, their need for qualified employ-
ees is increasing. A need that is difficult to satisfy. 
This transition of procurement and the some-
how insufficient academic consideration have been
the reason to analyze procurement in a detailed
empirical and scientific way. Therefore, three pro-
curement studies have been carried out to give
answers on questions that have been left un-
answered up to now. 
Based on this biggest procurement study series,
new procurement frameworks have been devel-
oped which help professionals of all industries to
find their way to more value creation in procure-
ment. These frameworks are called Supply Value
Management (SVM), Supply Infrastructure Man-
agement (SIM) and the Supply Value Maturity Model
(SVMM). These are interlinked and will be further
introduced in this article. While Supply Value Man-
agement describes how procurement can create
value for a company, Supply Infrastructure Man-
agement places the spotlight on what a company
needs to achieve this value creation. Finally, the
Supply Value Maturity Model assesses whether a
company’s procurement is rather seen as a basic
internal service provider, a more mature value cham-
pion or something in between.
With the last study, the III. Global Procurement
and SCM Study conducted in 2013, these frame-
works could be empirically proved. The specific sit-
uation of the chemical, pharmaceutical and health-
care industry are analyzed using these frameworks
to answer the question where the most important
value creation potentials of this industry lie. In addi-
tion, the major differences of good and bad per-
forming companies can be identified. 
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Based on the Supply Value Management, the
chemical, pharmaceutical and healthcare industry
shows a significant performance gap for all nine
value creation levers of procurement. A specific
value creation lever in this industry that is typical-
ly lower for other industries is risk (management). 
The performance for all seven different aspects
of the Supply Infrastructure Management is also
significantly lower compared to other benchmark
industries. The main performance gap for supply
infrastructure, shown by the analysis for the indus-
try, is the standing of procurement. This indicates
that the main current problem for procurement
departments in the focus industry is a low stand-
ing of procurement towards senior executives of
other functions.
According to the Supply Value Maturity Model,
the requested performance of procurement in the
chemical, pharmaceutical and healthcare industry
is quite high and mature. However, procurement
is not able to deliver the desired value creation. This
is mainly referring to the low standing procure-
ment processes and the missing contribution to
value creation by a good risk management and
innovation management (with suppliers).
As these results indicate, the potential value
creation levers of procurement go far beyond cur-
rent typical definitions of procurement which see
it as a function of acquiring the requested goods
at the right cost with right quality to a determined
point of time.
Before introducing the results concerning the
three frameworks in more detail, the study design
of the III. Global Procurement and SCM Study is dis-
played.
2 Study design
The III. Global Procurement and SCM Study was
a follow up to the two biggest procurement stud-
ies ever conducted in 2009 and 2011 with about
1,800 participants from 82 countries. It was con-
ducted by the Kellogg School of Management (one
of the Top 5 Business Schools of the world), the
American Purchasing Society, the International
Chamber of Commerce and the Valueneer GmbH.
Based on a questionnaire with 47 questions,
important topics of procurement were analyzed.
The questions were clustered to the following pro-
curement related topics:
1) Trends
2) Strategy
3) Organization, Controlling and Processes
4) Ethics and Chief Procurement Officer (CPO)
5) Risk Management.
Exemplary questions that were asked in the pre-
vious studies as well as in this study are:
Do you have a communicated procurement
strategy in your company?
Do you have a specific controlling of procure-
ment activities in your company?
Are procurement activities in your company
standardized and documented?
New questions focusing on trends and risk man-
agement were included in the III. Global Procure-
ment and SCM Study. To put an additional empha-
sis on sustainability and ethics, questions such as
Which instruments do you use to create a sus-
tainable procurement? 
Do you feel pressured at your company to behave
in an unethical way to better achieve targets
and goals?
were added.
For this study, more than 5,000 top executives
of renowned international companies were con-
tacted. In total, the III. Global Procurement and SCM
Study can refer to participants from 555 companies
from 66 countries around the globe. The entire
study series had participants from 94 countries.
Companies from the chemical, pharmaceutical and
healthcare industry are representing 9% of the par-
ticipants in the last study. The study participants
originate from all continents. North America, Asia
and Europe are represented to a similar extent. Also
companies from Africa and South America parti-
cipated and account together for around 16% of
the sample. The study examines all different busi-
ness sectors and company sizes.
The study covers all relevant decision levels, i.e.
senior managers and procurement experts. There-
fore, important operational and strategic questions
can be analyzed from a complementary point of
view. The data was gathered from July 2013 till
December 2013.
Against the background of the III. Global Pro-
curement and SCM Study, the insights on the three
procurement frameworks will be described in the
following for all industries in general. Additional-
ly, the industry analysis for the chemical, pharma-
ceutical and healthcare industry will be shown in
particular. 
3 Supply Value Management (SVM)
General definitions of procurement limit its
importance typically to a supply chain perspective.
In this context, procurement is often defined as the
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acquisition of goods and services at the best pos-
sible total cost of ownership to meet the needs of
the purchaser in terms of quality and quantity, time
and location (van Weele, 2010). From our perspec-
tive, these definition are not complete as they neg-
lect important value creation levers of procure-
ment. The operational perspective of procurement
is essential, but it shows just a part of the full value
creation potential of procurement. A definition of
procurement should take a more strategic perspec-
tive into account. How can procurement support
the strategy of the company?
According to Porter (1996), (1) strategy is a log-
ical concept to achieve a higher financial perform-
ance (e.g. ROCE) compared to competitors by (2) a
unique value proposition, (3) a different tailored
value chain, (4) activities that fit together and rein-
force each other, (5) involving clear trade-offs and
thus enabling (6) sustainable advantage. If pro-
curement should support the overall business strat-
egy, similar aspects have to be involved when defin-
ing the procurement strategy. Taking into consid-
eration Porter’s definition of strategy, the follow-
ing attributes could be derived easily for a company’s
procurement strategy:
1) Logically connected to the goal of long-term
superior financial performance
2) Maximizing value creation from supply and
suppliers
3) Fitting the company’s positioning and stra-
tegy
4) Adapting to other parts of the entire value
chain
5) Defining clear trade-offs within potential pro-
curement goals
6) Striving for sustainability with continual
improvement
If the goal of any strategy is to achieve a high-
er financial performance, one starting question for
any procurement strategy should be, how procure-
ment can influence financial performance.
Generally speaking, procurement can influence
a company’s financial performance by five key KPIs:
margin, revenue, risk, capital and taxation. So, pro-
curement can help a company in order to achieve
a better financial performance by better manag-
ing Total Cost of Ownership (TCO) leading to high-
er margins, by increasing revenues through pro-
curement, by reducing supply risks, by fewer required
(working) capital and lower taxation. 
These five key levers define the complete set of
aspects how procurement can influence the finan-
cial performance:
Margin: The way in which procurement is direct-
ly influencing a company’s margin is by its various
costs such as material costs, service costs, process
costs and personal costs. Because procurement typ-
ically spends the largest cost block, procurement
has a huge lever on a company’s total cost. Mar-
gin will therefore be called ‘cost’ in the Supply Value
Management framework illustrated in Figure 1. Due
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Figure 1 The nine value creation levers of Supply Value Management (SVM).
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to its high importance as a value creation lever, it
is allocated to the operational as well as to the
financial perspective of the SVM.
Revenue: The most important functions of a
company influencing revenues are typically not
procurement but sales, marketing or R&D. But pro-
curement’s effect on revenue should not be neg-
lected. Additionally, for a procurement person it is
very hard to estimate how and to which extent he
or she can influence a company’s revenue. There-
fore, ‘revenue’ has to be represented by a set of
levers which influence revenue and are easier to
understand, observe and influence from a procure-
ment perspective.
The first perspective on revenue is an opera-
tional one. The quality of the supplied goods defi-
nitely has an influence on the revenue. Addition-
ally, procurement has an influence on whether
important materials are available or not. Suppliers
who can react fast and flexible are helpful for boost-
ing sales when clients or business situations require
short term adaptations to changes. Thus, ‘quality’,
‘reliability’ and ‘speed’ form the operational per-
spective on revenue in the SVM framework.
There is a second growth perspective which is
also related to revenue and originating from dif-
ferentiation. This perspective is associated with
sourcing more innovative or sustainable products.
While there is a positive effect of more sustainable
products, there might as well be a negative effect
if not considered, e.g. by negative press because a
company is sourcing from a supplier that uses child
labor. ‘Innovation’ and ‘sustainability’ represent the
growth perspective in the SVM framework.
As revenue can be broken down to a growth
and an operational perspective, the influences are
represented by quality, reliability, speed, innova-
tion and sustainability in the SVM framework.
There is a third perspective in the SVM called
the financial perspective. It is represented by ‘risk’,
‘capital’ and ‘tax’ in the framework. As these are
common terms from a financial perspective and
easy to understand, a substitution with other more
observable terms from a procurement perspective
is unnecessary.
Risk: Procurement can influence a company`s
risks to a large extent. The volatility of material
costs or exchange rates are examples for that. Addi-
tionally, it can be affected by the risk of suppliers
going bankrupt or by the risk to be hugely affect-
ed from natural disasters or political unrest. 
Capital: Procurement has mainly two ways to
influence the capital needed: Accounts payable and
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stocks. Both are part of the working capital and
influence a company`s liquidity. Moreover, procure-
ment influences important make or buy or buy or
lease decisions which have an effect on the need
for capital.
Tax: Procurement can also influence a compa-
ny’s taxation e.g. by using procurement offices in
countries with lower taxation. Besides a potential
negative press on doing or not doing so, this is influ-
encing the financial performance of a company. 
From these five key levers of procurement on
the financial performance of a company, nine impor-
tant value creation levers can be derived. These
value creation levers are:
1) Cost - Key lever: Margin
2) Risk - Key lever: Risk
3) Capital - Key lever: Capital
4) Tax - Key lever: Tax
5) Sustainability - Key lever: Revenue
6) Innovation - Key lever: Revenue
7) Speed - Key lever: Revenue
8) Reliability - Key lever: Revenue
9) Quality - Key lever: Revenue.
These nine value creation levers together form
the SVM illustrated in Figure 1. This model has been
developed and tested on the background of the
procurement study series. The Supply Value
Management is a framework to handle trade-offs
and align the procurement strategy to the overall
business strategy. Based on the SVM, a company
can set up the main value creation levers for pro-
curement, derive KPIs and e.g. decide which sup-
pliers to choose. There might be a situation where
suppliers have the same or similar cost for a good
or service that is about to be bought. Additionally,
qualitative aspects are also equal. However, the
suppliers perform different on speed and reliabil-
ity. As the importance for these two aspects has
been defined in the SVM, the decision can be made
more easily as either speed or reliability has been
given a higher importance for sourcing decisions. 
The framework is considering by far more
aspects of procurement than typical supply chain
and operation focused definitions of procurement.
The operational perspective is of course an impor-
tant one and therefore also considered in the frame-
work, but there are additionally the financial and
growth perspective that need to be taken into
account. 
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Figure 2 Comparison of Supply Value Management (SVM) for all industries and the chemical, pharmaceutical and 
healthcare industry.
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Figure 3 Comparison of Supply Value Management (SVM) for companies of the chemical, pharmaceutical and healthcare
industry in quartile 1 and 4.
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3.1 Supply Value Management in the chemical,
pharmaceutical and healthcare industry
Based on the results of the III. Global Procure-
ment and SCM Study, the performance regarding
the nine value creation levers of all industries can
be compared with the performance of the chemi-
cal, pharmaceutical and healthcare industry. Per-
formances for all industries are illustrated in Fig-
ure 2. Shown in light grey is the average perform-
ance of the cross-industry benchmark for all par-
ticipants in the study regarding the ability to create
the specific value within procurement. The dark
grey area shows the gap between the current per-
formance and the aspiration target of each of the
nine value creation levers. If the dark grey area is
large, there is a significant difference between
aspired and achieved performance for a value cre-
ation target. 
By looking at the Supply Value Management for
all industries, the highest gaps are shown in the
areas of cost, quality and reliability. Although these
topics might be seen as the ‘old perspective on pro-
curement’, the average of all companies is still strug-
gling in achieving the aspired value creation tar-
gets. In addition to the mentioned levers, there is
also a relevant average gap for risk, speed and inno-
vation. Regarding capital, tax and sustainability,
the average of the participants state that they do
not have a huge gap between performance and
importance for these levers. 
Taking a look at the analysis for the chemical,
pharmaceutical and healthcare industry shows that
the importance gap regarding most of the value
creation levers is higher than compared to the cross-
industry analysis. This means that in comparison
to the industry average, this industry has a much
higher performance problem regarding desired and
achieved value creation. In addition to that, the
importance and subsequently the required value
contribution for the value creation levers are expect-
ed to be higher compared to an analysis for all
industries. 
The highest gaps for value creation are in the
fields of cost, quality and risk. While reliability already
shows a significant gap, the gap for risk is even
higher. The high importance of risk management
in the chemical, pharmaceutical and healthcare
industry should not be surprising. However, the
large gap for such an important topic in this indus-
try is an important negative indicator. Additional-
ly to the already mentioned aspects, the industry
can improve on reliability, speed and innovation. 
Taking a closer look at the performance and
importance in the chemical, pharmaceutical and
healthcare industry for good and bad performing
companies regarding procurement shows signifi-
cant differences for the Supply Value Management.
The different importance and performance for quar-
tile 1 and quartile 4 companies are illustrated in
Figure 3. The companies have been grouped into
four quartiles based on their average procurement
performance. Quartile 1 therefore represents par-
ticipants with a good procurement performance.
Quartile 4 comprises companies with the worst
procurement performance. Each quartile repre-
sents 25% of the survey participants.
It becomes obvious that the problems for good
and bad performing companies in the chemical,
pharmaceutical and healthcare industry are quite
different. Good performing companies from this
industry meet their cost targets and can refocus
their attention to areas like quality, reliability, risk
and innovation. Companies from quartile 4 do not
achieve their targets regarding their most basic
KPI, i.e. cost reduction. As a result, they have fewer
resources to focus on other value creation levers.
Subsequently, they have a bad performance con-
cerning quality and reliability and a very bad per-
formance regarding risk (management) compared
to their (already low) aspiration. 
Another interesting aspects is also revealed.
Growth aspects in general seem, on average, to be
less important for bad performing companies. The
good performing companies even see innovation
as one value creation lever which they need to
improve while this is almost completely unrealized
by bad performing companies. What both quar-
tiles have in common is the fact that they state
they need to improve on risk. 
In total, the importance of all value creation
levers for good performing companies in the chem-
ical, pharmaceutical and healthcare industry is sig-
nificantly higher and good performing companies
consider more different aspects they need to work
on. 
4 Supply Infrastructure Management (SIM) 
Supply Value Management covers all levers by
which procurement directly creates value for a com-
pany. But there are indirect ones as well, i.e. aspects
that define procurement’s infrastructure. There-
fore, another framework has to be developed. This
framework considers the supporting aspects and
resources of procurement for value creation. This
framework is called Supply Infrastructure Manage-
ment. The SIM framework has like the SVM frame-
work been set up on the empiric findings of the
three global procurement studies conducted.
There are seven different aspects that this frame-
work takes into account which can be grouped into
four different areas: strategy, tools, people and
organization. It is noteworthy that this framework
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is not about direct value creation. Each of the aspects
that is part of this framework is supporting or rein-
forcing the value creation levers of the SVM, but
none of the aspects is creating value by itself. For
example, standardized processes, a new IT systems
or more or better employees are not creating any
value by their existence. However, they can provide
the necessary resources, transparency etc. for pro-
curement to e.g. better achieve cost targets by high-
er transparency or reduced time and effort spent
on managing tenders. 
The four areas of procurement’s infrastructure
are described in the following:
Strategy: Based on the performance analysis of
the study series, strategy is the most important
aspect supporting the value creation of procure-
ment. The strategy defines clear trade-offs for the
nine value creation levers and provides guidance
e.g. on whether quality is more important than cost
or vice versa. This is highly important as not all value
creation levers have the same importance for a
company. Once these trade-offs are defined, they
enable the company and procurement to better
create value as they support the decision-making
process. A lot of companies lack these and have
problems to find optimum solutions when they
have to choose between suppliers with different
advantages and disadvantages. Additionally, it is
important to link the procurement strategy to the
overall business strategy.
Tools: The two aspects of the area ‘tools’ are
controlling and processes. The controlling enables
procurement to measure its performance and also
shows the value contribution to other departments.
The improvement of processes e.g. by standardi-
zation frees capacity that is currently blocked by
operative tasks which are not creating any value
for the company. The capacity can then be used for
more value creation tasks e.g. by leveraging new
potential suppliers for value creation. 
People: The CPO and the employees are of course
an essential part of the supply infrastructure. And
for a lot of companies today, lacking good people
and a strong leadership in procurement are main
bottlenecks when willing to improve procurement
performance and realize increased value creation.
Organization: The organizational structure of
procurement does as well influence how procure-
ment’s infrastructure can contribute to a better
value creation. For example, the standing of pro-
curement is important as it influences at which
process step procurement is involved in buying
decisions. A centralized or decentralized procure-
ment organization also affects how procurement
can or cannot create value e.g. by bundling sup-
plies.
Supply Value Management - A benchmarking study and a new theoretical
approach 
Figure 4 The seven areas of Supply Infrastructure Management (SIM).
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The framework of SIM is illustrated in Figure 4
and consists of the following seven areas: 
1) Strategy
2) Controlling
3) Processes
4) Leadership
5) Employees
6) Structure
7) Standing.
The Supply Infrastructure Management is an
easy to use framework illustrating the current and
aspired status quo for the supporting aspects of
Supply Value Management. Therefore, the two mod-
els should ideally be considered in combination
and not isolated.
4.1 Supply Infrastructure Management in the
chemical, pharmaceutical and healthcare indus-
try
The analysis of the III. Global Procurement and
SCM Study shows that there is a significant gap
between importance and performance for all seven
supporting aspects of the SIM for all industries. As
for the Supply Value Management, the dark grey
areas indicate the gaps which show that the aver-
age performance is lower than the average impor-
tance. In case there is no dark grey area, the impor-
tance and performance have been evaluated as
being equal. 
As illustrated in Figure 5, companies perform
best regarding processes, controlling and (to a lower
extent) strategy. This is not surprising because the
same definitions that focus the value contribution
of procurement in the areas of cost, quality and
reliability define the core of procurement by its
nature of optimizing material flows. Taking this
process focused approach as a starting basis for
procurement is very common across all industries.
The gap is highest for employees, structure and
leadership within the cross-industry sample. The
analysis illustrates one of the major problems that
procurement is currently facing. In general, there
are too few employees with the right skills avail-
able and subsequently many companies state that
they would need additional resources. In addition,
employees are rather not having the expected
qualification level. Most companies also miss an
incentive structure supporting the value creation
of procurement e.g. in the field of cost. Providing
incentives in reliance to cost saving targets would
be a smart approach to increase the performance
of these employees and procurement as a whole. 
But also procurement’s interface to senior exec-
utives is something that needs to be improved. Pro-
curement many times misses to have a voice in the
board of directors which is an indication on the lim-
ited power procurement has in a company. This fact
is also linked to the leadership capabilities of the
CPO. Strong CPOs will manage to improve this inter-
face and direct more attention towards procure-
ment. The leadership capabilities are also linked to
the fact that the CPO often originates from oper-
ations. This would shape the mindset of the CPO
to a large extent, so that the operational value cre-
ation levers push other levers into the background.
Subsequently, some value creation potential is left
unexploited. 
The challenges for the chemical, pharmaceuti-
cal and healthcare industry are similar to the over-
all industry sample but showing different centers
of gravity. However, what becomes obvious from
Figure 5 is that the performance gaps for most
aspects of SIM are higher than in the analysis of all
industries. Only for employees and leadership, there
is a performance gap that is not as high as for the
cross-industry sample. As indicated for the SVM,
the gaps for the chemical, pharmaceutical and
healthcare industry are also for the SIM significant-
ly higher than for the cross-industry average (with
exception of employees and leadership). The high-
est benchmark gaps are present in the fields of con-
trolling, standing and structure. Most obvious, the
standing of procurement in this industry is below
the average cross-industry benchmark.
As indicated earlier in this article, the lower
standing of procurement in the chemical, pharma-
ceutical and healthcare industry should not be a
big surprise as the standing of departments like
sales and especially R&D is quite high in this indus-
try. The interface to senior executives is also not as
good as in the cross-industry benchmark. This might
to some extent also be related to the gap existing
for controlling. Once the value contribution of pro-
curement is not measured and communicated
transparently, the standing is weakened. Although
all aspects of the SIM show significant perform-
ance gaps, the gaps for employees and leadership
are smaller than for the cross-industry analysis. The
chemical-related sector with a lot of large multi-
nationals seems to be better than average able to
attract good people in sufficient numbers who are
led by a CPO with adequate leadership capabilities.
Nevertheless, the chemical, pharmaceutical and
healthcare industry still needs to improve on these
aspects.
A closer look at what good and bad performing
companies in the chemical, pharmaceutical and
healthcare industry are doing differently is illus-
trated in Figure 6. The good performing companies
of this industry do not show any significant bench-
mark gaps in the field of SIM. They are meeting
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Figure 5 Comparison of Supply Infrastructure Management (SIM) for all industries and the chemical, pharmaceutical and  
healthcare industry.
Figure 6 Comparison of Supply Infrastructure Management (SIM) for companies of the chemical, pharmaceutical and 
healthcare industry in quartile 1 and 4.
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almost all performance targets for the seven aspects
of SIM. Only slight necessary improvements for
standing and employees for the top performers
can be identified. 
The picture for the bad performing companies
in the chemical, pharmaceutical and healthcare
industry is completely different. These companies
show a very high benchmark gap for all areas of
the SIM. These gaps are highest for strategy and
standing. If we compare this with Figure 3, we can
identify that bad performing companies do not
seem to really have a procurement strategy as pro-
curement for them mainly focusses on two aspects,
i.e. cost and quality. Again, the gap for employees
is even quite low for bad performing companies
which underlines the fact that employees do not
seem to be one of the major infrastructure prob-
lems for this industry. 
5 Supply Value Maturity Model (SVMM)
A lot of the discussion has been led by the fact
whether a company is performing good or bad.
Based on the SVM framework, there are four key
value creation clusters how a company can gener-
ate value in procurement: cost, operations, finance
and growth. The question is which value creation
cluster is the best indicator for an excellent per-
forming company. 
Figure 7 displays the average performance for
different value creation strategies. These strate-
gies are clustered into four value creation cluster
mentioned above (cost, operations, finance and
growth). A procurement strategy is thus defined
as the sum of the value creating clusters which a
company perceives to be very important for its pro-
curement. As illustrated, there are 16 different com-
binations like ‘cost and operations’ or ‘cost, opera-
tions, finance and growth’ possible. Figure 7 shows
the average procurement performance of compa-
nies choosing a certain strategy cluster. In addition,
listing the probability of the value creation clus-
ters reveals how common a certain value creation
cluster is.
From the bottom to the top of Figure 7, the aver-
age performance of a company is increasing. The
graphic also shows that the better the perform-
ance, the more complex the strategy becomes as
more value creation clusters are considered. 
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Figure 7 Strategic importance of aggregated value creation clusters.
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Figure 7 shows that companies with a higher
procurement performance do not take complete-
ly different value creation clusters into account.
The main distinction between good and bad per-
formers is that the good performers see their strat-
egy and their everyday work as being more com-
plex.
There are five common combinations, each with
a probability above 10%, which are marked in bold.
What might be somewhat surprising is the fact
that a company that is only focusing on cost as
value creation target is performing similar to a com-
pany that has not defined any value creation tar-
get at all. So, cost alone cannot be the solution for
a good procurement. Figure 7 also shows an inter-
esting pattern: the more cluster a strategy con-
tains, the better the performance. And there seems
to be natural order when adding any cluster, start-
ing with cost, then operations, then finance and
finally growth. 
The SVMM is a framework which combines these
different strategies for value creation and their
related average performances. The different dimen-
sions that are added as value creation levers form
different stages a company can pass through. The
SVMM shows the following five value stages with
typically increasing overall performance:
0) No strategy
1) Cost focus
2) Cost & operations focus
3) Cost, operations & finance focus
4) Cost, operations, finance & growth focus.
However, stating that there is a specific value
creation strategy in a company is not necessarily
reflecting whether a company is also able to achieve
the value creation targets that have been put in
place. Therefore, the value creation strategies have
to distinguish aspired and delivered value creation
targets. The stages with the value targets added
and the main value creation problems of each strat-
egy are illustrated in Figure 8. 
As it becomes clear from the illustration, there
is a different main value problem for each of the
stages. Subsequently, not all aspects of a supply
value creation category are in focus once a new
dimension is added to the value target. For
stage 1, the main value problem is cost. In the next
stage the operational perspective is added as a
value cluster while the main value creation prob-
lem lies now in quality. For stage 3, the new dimen-
sion is finance and the main value creation lever
most companies in this stage are struggling with
is risk. In the last stage where procurement is seen
as ‘Value Champion’, the added dimension is growth.
Companies in this final stage of the Supply Value
Maturity Model are mainly facing challenges in
terms of innovation in order to achieve their value
creation targets. 
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Figure 8 The five stages of the Supply Value Maturity Model (SVMM). 
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There is another interesting aspect of the SVM
Model shown in Figure 8. Stage 0 is maybe the level
where procurement has had its starting point. Based
on the analysis, only 13% of companies are located
at that stage (see Figure 9), so that most of the
companies have already passed it by adding cost
as a first value creation lever. However, there are
companies who do or did deliver on this value cre-
ation target while others are or were unable to do
so. Therefore, stage 1 and all following stages dis-
tinguish between aspired and delivered value cre-
ation. Comparing what companies aspire and what
they are able to deliver shows that only the minor-
ity is able to deliver. Once a company proceeds from
one stage to another without having been able to
achieve the value creation targets of the previous
stage, it is clear that company will have huge prob-
lems in delivering regarding the value creation tar-
gets of that new stage. As a consequence, a com-
pany will not be able to move directly from stage
0 to stage 5 but rather has to proceed stagewise
along the maturity model.
5.1 Supply Value Maturity Model for the chemical,
pharmaceutical and healthcare industry
Taking a closer look at where companies in gen-
eral are positioned in the Supply Value Maturity
Model and where the chemical, pharmaceutical
and healthcare industry in particular is situated is
shown in Figure 9. Looking at the average of all
companies shows that most companies are either
in stage 2 with cost and operations or in stage 4
with cost, operations, finance and growth as value
creation targets. 
The illustration also shows that not all value
creation levers of a specific value creation catego-
ry are added once another cluster added. In case of
adding finance, typically only risk is added as a value
creation lever to the already targeted levers. 
Comparing the distribution of the chemical,
pharmaceutical and healthcare industry to the dif-
Figure 9 Proportion of chemical, pharmaceutical and healthcare companies in the five stages of the SVM Model.
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ferent stages of the SVM Model shows that the
companies are almost spread in the same way as
the cross-industry sample. The analysis also shows
that the main differences can be found in stages
3 and 4. Here, the aspired value creation of procure-
ment is quite high but the procurement depart-
ments of the chemical, pharmaceutical and health-
care industry are not able deliver highly on the
expected value creation.
Taking the SVM Model step by step starting with
stage 0 shows that only 10% of the companies from
this industry are still in the earliest stage. At this
stage, procurement is seen as an internal service
provider and its value contribution is very limited.
In stage 1, which is focusing only on cost as a value
creation lever, there are 19% of the companies in
total. Although cost as the main value creation lever
is not that sophisticated, only 2% of the companies
from the chemical, pharmaceutical and healthcare
industry are able to deliver the aspired value cre-
ation target, so that the effective value creation of
companies in stage 0 and 1 is very similar.
A little more companies are located in stage 2
where the focus of value creation additionally lies
on the value creation levers quality and reliability.
In this stage, 8% of a total of 22% of the companies
are able to deliver on the value creation target. In
stage 3, with risk as additional value creation tar-
get, are most of the achievers. 12% of the compa-
nies are able to deliver the aspired value creation.
The main value creation problem is that compa-
nies of the chemical, pharmaceutical and health-
care industry are not able to deliver the aspired
value creation for risk. This is again underlining the
fact that the industry is having a major problem
with this value creation lever as already elaborat-
ed before. 
Finally, there is stage 4 where most of the com-
panies do find themselves in. Almost one third (32%)
of the companies states that according to their
strategy they are at this maturity stage. However,
only 8% of the companies are able to really deliv-
er the aspired value from a procurement perspec-
tive. In other words, only 8% of the companies in
this industry are really ‘value champions’ – for the
average cross-industry sample, this number increas-
es to 15%. The main problem in stage 4 is innova-
tion (and to a lesser extent sustainability) which is
added to the (sometimes still unsolved) value cre-
ation problem of stage 3. The companies try to
increase procurement’s value creation by sourcing
innovate products or technologies from their sup-
plier but miss to exploit the power for growth oppor-
tunities from existing and potential new suppliers.
This fact has its root cause in the Supply Infrastruc-
ture Management where procurement is strug-
gling with achieving the necessary standing for
having the necessary power to drive value creation.
In total, the number of ‘Value Champions’, i.e.
those companies who are able to deliver on all value
creation clusters in stage 4, is quite low. But at the
same time, the aspired value creation of procure-
ment in the chemical, pharmaceutical and health-
care industry is quite high. That way, most compa-
nies are not able to deliver the aspired value cre-
ation targets. This is already based on the results
derived by analyzing the Supply Value Manage-
ment and Supply Infrastructure Management where
risk management and the standing of procurement
have already been outlined as major bottlenecks.
6 Conclusion
There are three frameworks for procurement
provided in this article. First, there is Supply Value
Management that is clearly defining which value
creation levers procurement really has. It is a frame-
work that helps any company to choose what is
really important for procurement in a specific indus-
try and company e.g. to decide which suppliers to
choose. 
In addition to this framework, there is Supply
Infrastructure Management, which is combining
all relevant supporting aspects for value creation
by the SVM. Its seven aspects are supporting the
nine value creation levers and are not value creat-
ing by themselves. The SIM answers which resources
are needed to create value with procurement.
Finally, there is the Supply Value Maturity Model.
This framework allows to allocate a company regard-
ing its procurement maturity to five potential stages.
From stage 0 where procurement is seen as an
internal service provider to stage 4 where procure-
ment is value champion delivering on the cost, oper-
ations, finance and growth value creation clusters.
Each of the stages additionally distinguishes
whether a company only aspires or really delivers
on the value creation clusters. 
A close look at the Supply Value Management
framework for the chemical, pharmaceutical and
healthcare industry revealed major value creation
potentials in the field of cost, risk and quality. In
comparison to all industries, it becomes obvious
that the performance for all value creation levers
is significantly lower. For most companies in this
industry, it would therefore be a good advice to
improve on risk, quality and cost to achieve a bet-
ter value contribution of procurement. 
The main reason why companies are struggling
with achieving higher value creation resulting in a
better procurement performance can be found in
the Supply Infrastructure Management. As men-
tioned, the chemical, pharmaceutical and health-
care industry has to improve on all aspects of the
SIM. The activities to improve SIM are concerning
a better connection to the executive management
and increasing the standing of procurement with-
in the company. Before doing so, an improved con-
trolling with more transparency of procurement’s
value contribution should be implemented. 
Most of the companies of the chemical, phar-
maceutical and healthcare industry are to be found
in stage 2 and stage 4 of the Supply Value Maturi-
ty Model, meaning they focus to a minimum on
cost and operational aspects. However, the differ-
ences for the aspired and delivered value creation
in the SVM Model are highest in stages 3 and 4.
From a value creation perspective, the major prob-
lem has to been seen in the field of risk while from
an infrastructure perspective, the main problem is
the standing of procurement within the company.  
The chemical, pharmaceutical and healthcare
industry is an industry with high aspirations regard-
ing procurement but only average performance,
which has its root cause in a too low standing of
procurement by senior executives, leading to a sit-
uation where procurement has huge problems to
deliver on advanced procurement value creation
levers like risk and innovation management of sup-
pliers. 
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